For a lot of people, weight is not really the whole story. What sits behind it is the worry about what carrying extra weight is doing to the heart, especially for anyone living with type 2 diabetes, raised blood pressure or a family history of heart problems. So when a brand new weight loss treatment arrives, a fair question to ask is not only how much weight it takes off, but what it does to your cardiovascular health.
For Foundayo, there is now real data to point to, from a large study called ACHIEVE-4. This guide sets out what that study actually showed, and just as importantly what it did not, so you can weigh it up honestly. If you are considering Foundayo in Swansea, our team can talk it through with you in person. For the full overview of the treatment, start with our complete guide to Foundayo in Swansea.
The honest headline
ACHIEVE-4 was a heart-safety study in people with type 2 diabetes at higher cardiovascular risk. It showed Foundayo is reassuring for the heart rather than harmful, alongside improvements in blood pressure and cholesterol. It did not prove Foundayo prevents heart attacks, and its striking result on survival is an early signal that needs confirming, not a settled fact.
What ACHIEVE-4 Was
ACHIEVE-4 is the longest phase 3 study of Foundayo so far. It enrolled more than 2,700 people across 15 countries, all of whom had type 2 diabetes and were at elevated cardiovascular risk. Rather than comparing Foundayo against a dummy tablet, it compared it against insulin glargine, a long-established diabetes treatment. That is an important detail: the benchmark was an active, real-world medicine, not a placebo, which makes the comparison a demanding one.
The main purpose of a study like this is to answer the question every regulator asks of a new metabolic medicine: does it keep the heart safe over time? For a treatment that many people take for years, that reassurance matters as much as the number on the scales.
What the Study Showed
There are three findings worth understanding, and it is worth being precise about each, because this is exactly the kind of data that gets oversimplified elsewhere.
1. Cardiovascular safety. On the study’s main measure, major adverse cardiovascular events such as heart attack, stroke and cardiovascular death, Foundayo was shown to be non-inferior to insulin glargine. In plain terms, it did not increase cardiovascular risk compared with a well-understood treatment. That is the reassurance the study set out to provide, and it delivered it. It is worth being clear that this is a safety result rather than proof that Foundayo actively reduces those events.
2. Improvements in cardiovascular risk factors. Alongside that, the study recorded meaningful improvements from the starting point in several measures that matter for heart health: systolic blood pressure, triglycerides, non-HDL cholesterol, and a marker of inflammation called high-sensitivity CRP. These are the day-to-day numbers a clinician actually tracks, and moving them in the right direction is a genuine plus.
3. An early signal on survival. In a pre-planned secondary analysis, the risk of death from any cause was lower in the Foundayo group than the insulin glargine group. This is a striking and encouraging finding. It also comes with an important caveat: it was a secondary analysis that was not statistically controlled in the same rigorous way as the main result, which means it is best treated as a promising signal to be confirmed by further research, not as an established benefit you can bank on. We would rather tell you that plainly than overstate it.
Why Heart Health Matters with Weight Treatment
Carrying excess weight, and living with type 2 diabetes, both place extra strain on the heart and blood vessels over time, and they often travel together with raised blood pressure and cholesterol. That is why a weight treatment that is kind to the heart, and that nudges those other numbers in the right direction, is worth more than one judged on weight loss alone. It is also why we build a blood pressure check and a weight check into every Foundayo review as standard, rather than simply issuing a repeat prescription.
If your interest in Foundayo is partly driven by type 2 diabetes, that is a distinct licensed use with its own considerations, and we cover it in our guide to Foundayo and type 2 diabetes.
Who This Data Is Most Relevant To
The ACHIEVE-4 findings are most directly relevant to people with type 2 diabetes who are at higher cardiovascular risk, and to anyone weighing up a weight treatment with a family history of heart problems on their mind. It is worth being clear about what Foundayo is and is not: it is a treatment for weight management and, separately, for blood sugar control in type 2 diabetes. It is not a heart medicine, and it is not a replacement for any cardiac treatment your GP or cardiologist has prescribed. If you have a heart condition, keep taking what you have been prescribed and tell your prescriber about it, so any decision about Foundayo is made with the full picture.
Who Foundayo Is For, and How It Is Taken
Foundayo is licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, prediabetes, high cholesterol or cardiovascular disease, used together with a reduced-calorie diet and more physical activity. It is a once-daily tablet that can be taken at any time of day, with or without food or water, which sets it apart from the injections and from the Wegovy pill. A full assessment at your first appointment establishes whether it is suitable and right for you.
As with other GLP-1 medicines, the most common side effects are gastrointestinal: nausea, vomiting, diarrhoea and constipation, usually most noticeable early on or after a dose increase. Foundayo is not suitable for everyone, including during pregnancy and breastfeeding. Your prescriber will go through your full history, the benefits and the risks, before you start.
Why Choose Medihub
Heart-health data deserves a proper conversation, not a tick-box on a website. At Medihub you are seen in person by a named Independent Prescriber: Osama Al-Saied at Killay, GPhC number 2222112, and Carwyn Jones at Pontarddulais, both publicly verifiable on the pharmacy regulator’s register. Because we see you face to face, we can check your blood pressure and weight at each review and factor your wider health into the plan, which matters more for a medicine like this than for almost anything else.
Both branches offer the same service. Killay on Gower Road, SA2 7BA, serves Killay, Sketty, West Cross and the Gower peninsula. Pontarddulais on St Teilo Street, SA4 8ST, is convenient for Pontarddulais, Gorseinon, Llansamlet and Morriston, and the wider Swansea area.
Weighing up Foundayo with your heart health in mind?
Book a consultation at our Killay or Pontarddulais branch and we will talk it through properly, with a blood pressure check included.
Frequently Asked Questions
Is Foundayo safe for the heart?
In the ACHIEVE-4 study, in people with type 2 diabetes at raised cardiovascular risk, Foundayo did not increase the risk of major cardiac events compared with insulin glargine, and it improved several heart-health markers such as blood pressure and cholesterol. That is a reassuring safety result. As with any medicine, your own suitability is assessed individually at your consultation.
Does Foundayo prevent heart attacks and strokes?
The study did not prove that. It showed Foundayo does not raise cardiovascular risk (non-inferiority to an active treatment), rather than showing it actively lowers heart attacks and strokes. It is honest to describe it as heart-safe, not heart-protective in that stronger sense.
I read Foundayo lowers the risk of death. Is that true?
ACHIEVE-4 did find fewer deaths in the Foundayo group, which is genuinely encouraging. However, that came from a secondary analysis that was not held to the same statistical standard as the main result, so it is best understood as an early signal that needs confirming in further research, not a proven benefit. We would rather be straight with you about that than overclaim it.
Do these results apply to me if I do not have diabetes?
Not directly. ACHIEVE-4 studied people with type 2 diabetes at higher cardiovascular risk, so the figures cannot simply be assumed to apply to everyone. They are still useful context, but your own likely benefit is individual, which your prescriber will discuss with you.
Should I stop my heart or blood pressure medication if I start Foundayo?
No. Foundayo is not a replacement for cardiac or blood pressure treatment. Keep taking anything your GP or cardiologist has prescribed, and never stop a medicine without speaking to the clinician who prescribed it. Tell your Foundayo prescriber about all your current medicines so decisions are made with the full picture.
Can I get Foundayo in Swansea?
Yes. Medihub Pharmacy offers Foundayo privately at both its Swansea branches, Killay and Pontarddulais, with a face-to-face assessment and a blood pressure check at each review. No GP referral is needed.
The heart-health picture is one of the more encouraging things about Foundayo, provided it is read honestly. If it is part of what is drawing you to the treatment, book a consultation at your nearest Swansea branch, or read our complete guide to Foundayo in Swansea for the full overview.
Reviewed and medically verified by
Osama Al-Saied, Independent Prescriber
GPhC Number: 2222112 | Independent Prescriber
Medihub Pharmacy, Killay and Pontarddulais, Swansea
Verify on the GPhC register
Last reviewed: 13 September 2026 · Medically reviewed ✓
